An Overview of the ARANOTE Trial

Advanced Prostate Cancer Treatment Strategies

Panel Introduction

Featured Expert:

• Neal D. Shore, MD, FACS: Medical oncologist and urologist at Carolina Urologic Research Center, Myrtle Beach, South Carolina. Dr Shore is a recognized researcher in urologic oncology with expertise in clinical trials for advanced prostate cancer treatments.

Expert Specialty Areas

• Urologic oncology
• Clinical research in metastatic hormone-sensitive prostate cancer (mHSPC)
• Novel androgen receptor pathway inhibitors
• Prostate-specific antigen response as predictive biomarker

ARANOTE Trial Overview

Key Themes:

• Phase 3 clinical trial evaluating darolutamide plus ADT in patients with mHSPC
• Trial design and methodology
• Significant efficacy outcomes

Expert Insights:

• Dr Shore provided an overview of the ARANOTE trial design, which evaluated darolutamide in combination with androgen deprivation therapy (ADT) for patients with mHSPC.
• The discussion highlighted the topline results demonstrating clinical benefit with this treatment approach.